Feb 18th 2013 - Edison Investment Research today published a report on quickview entitled "Lixi Prospects See Saw". In summary, the report says:
A surprise regulatory setback for Novo Nordisk’s Tresiba has suddenly improved the prospects for Zealand’s key partnered programme just days after they were dashed. Thus, the setback that came with the disclosure by Sanofi of a delay in the development of the Fix-Flex combination product has been somewhat offset by the delay to Novo’s competing insulin/GLP-1 agonist combination, as a result of the FDA’s rejection of Tresiba. While uncertainty remains about the development timelines for Sanofi’s combination product, the shape of the future diabetes landscape has now shifted back in its (and thus Zealand’s) direction. Furthermore, after a 20% fall, Zealand’s share price has yet to reflect this new situation.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »